| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
|
Daniel, Catherine
|
|
|
|
4 |
p.
|
article
|
| 2 |
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
|
Piper-Vallillo, Andrew J.
|
|
|
|
4 |
p.
|
article
|
| 3 |
ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
|
Schoepflin, Zachary R.
|
|
|
|
4 |
p.
|
article
|
| 4 |
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
|
Ricciuti, Biagio
|
|
|
|
4 |
p.
|
article
|
| 5 |
Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report
|
Diep, Raymond
|
|
|
|
4 |
p.
|
article
|
| 6 |
Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors
|
Sun, Thomas Yang
|
|
|
|
4 |
p.
|
article
|
| 7 |
Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
|
Agar, Camille
|
|
|
|
4 |
p.
|
article
|
| 8 |
Brief Report: Prognostic Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung
|
Abu Rous, Fawzi
|
|
|
|
4 |
p.
|
article
|
| 9 |
Capillary Leak Syndrome With Pulmonary Edema Preceded by Organizing Pneumonia Caused by Combination Therapy With Nivolumab and Ipilimumab: A Case Report
|
Tachi, Hiroaki
|
|
|
|
4 |
p.
|
article
|
| 10 |
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
|
Jo, Hitomi
|
|
|
|
4 |
p.
|
article
|
| 11 |
Comprehensive Analysis of Clinical Logistic and Machine Learning-Based Models for the Evaluation of Pulmonary Nodules
|
Zhang, Kai
|
|
|
|
4 |
p.
|
article
|
| 12 |
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
|
Kareff, Samuel A.
|
|
|
|
4 |
p.
|
article
|
| 13 |
Development and Validation of Diffuse Idiopathic Pulmonary Neuroendocrine Hyperplasia Diagnostic Criteria
|
Sazonova, Olga
|
|
|
|
4 |
p.
|
article
|
| 14 |
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
|
Ishida, Masaki
|
|
|
|
4 |
p.
|
article
|
| 15 |
Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC
|
Lee, Jay M.
|
|
|
|
4 |
p.
|
article
|
| 16 |
Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial
|
Lu, Shun
|
|
|
|
4 |
p.
|
article
|
| 17 |
Erratum
|
|
|
|
|
4 |
p.
|
article
|
| 18 |
Erratum
|
|
|
|
|
4 |
p.
|
article
|
| 19 |
Exon 20-Mutated NSCLC: Extending the Data Set to Allow the Recognition of Potential Causes
|
van Zandwijk, Nico
|
|
|
|
4 |
p.
|
article
|
| 20 |
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
|
Szlosarek, Peter W.
|
|
|
|
4 |
p.
|
article
|
| 21 |
First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
|
Hayashi, Hidetoshi
|
|
|
|
4 |
p.
|
article
|
| 22 |
Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy
|
Chen, Hui-Zi
|
|
|
|
4 |
p.
|
article
|
| 23 |
Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
|
Mäkinen, Netta
|
|
|
|
4 |
p.
|
article
|
| 24 |
Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
|
Xu, Shiting
|
|
|
|
4 |
p.
|
article
|
| 25 |
Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis
|
Smeltzer, Matthew P.
|
|
|
|
4 |
p.
|
article
|
| 26 |
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors
|
Meyers, Daniel E.
|
|
|
|
4 |
p.
|
article
|
| 27 |
Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
|
Gautschi, Oliver
|
|
|
|
4 |
p.
|
article
|
| 28 |
Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
|
Young, Patricia A.
|
|
|
|
4 |
p.
|
article
|
| 29 |
Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma
|
Belderbos, Robert A.
|
|
|
|
4 |
p.
|
article
|
| 30 |
Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
|
Cravero, Paola
|
|
|
|
4 |
p.
|
article
|
| 31 |
Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors
|
Ünal, S.
|
|
|
|
4 |
p.
|
article
|
| 32 |
LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
|
Alexander, Marliese
|
|
|
|
4 |
p.
|
article
|
| 33 |
Medicolegal Considerations in Multidisciplinary Cancer Care
|
Karas, Pamela L.
|
|
|
|
4 |
p.
|
article
|
| 34 |
Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): Measurement Properties and Estimated Clinically Meaningful Thresholds From a Phase 3 Study
|
Williams, Paul
|
|
|
|
4 |
p.
|
article
|
| 35 |
Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
|
Jiao, Yuyan
|
|
|
|
4 |
p.
|
article
|
| 36 |
Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
|
Haratake, Naoki
|
|
|
|
4 |
p.
|
article
|
| 37 |
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
|
Thompson, Jeffrey C.
|
|
|
|
4 |
p.
|
article
|
| 38 |
Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal NTRK1 Fusion: Case Report
|
Boulanger, Mary C.
|
|
|
|
4 |
p.
|
article
|
| 39 |
Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy
|
Ao, Yanyun
|
|
|
|
4 |
p.
|
article
|
| 40 |
Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
|
Tchekmedyian, Nishan
|
|
|
|
4 |
p.
|
article
|
| 41 |
Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report
|
Olaechea, Santiago
|
|
|
|
4 |
p.
|
article
|
| 42 |
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases
|
Zhang, Qing
|
|
|
|
4 |
p.
|
article
|
| 43 |
Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma
|
Ninomiya, Hironori
|
|
|
|
4 |
p.
|
article
|
| 44 |
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
|
Nishio, Makoto
|
|
|
|
4 |
p.
|
article
|
| 45 |
Reply to Cortellini A
|
Ricciuti, Biagio
|
|
|
|
4 |
p.
|
article
|
| 46 |
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
|
Ahmadzada, Tamkin
|
|
|
|
4 |
p.
|
article
|
| 47 |
Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
|
Gibson, Amanda J.W.
|
|
|
|
4 |
p.
|
article
|
| 48 |
Seize the Opportunity With Small Tissue Samples: The Tailor Teaches!
|
Trisolini, Rocco
|
|
|
|
4 |
p.
|
article
|
| 49 |
Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
|
Stabellini, Nickolas
|
|
|
|
4 |
p.
|
article
|
| 50 |
Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study
|
Chen, Tianxiang
|
|
|
|
4 |
p.
|
article
|
| 51 |
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
|
Lawrence, Marissa N.
|
|
|
|
4 |
p.
|
article
|
| 52 |
Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
|
Ito, Masaoki
|
|
|
|
4 |
p.
|
article
|
| 53 |
Stigma May Exacerbate Disproportionately Low Guideline-Concordant Treatment Rates for Patients With Advanced-Stage Lung Cancer in the United States
|
Peng, Terrance
|
|
|
|
4 |
p.
|
article
|
| 54 |
Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC
|
Moore, Sara
|
|
|
|
4 |
p.
|
article
|
| 55 |
The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
|
Cortellini, Alessio
|
|
|
|
4 |
p.
|
article
|
| 56 |
The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma
|
Wheatley-Price, Paul
|
|
|
|
4 |
p.
|
article
|
| 57 |
Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage
|
Zhang-Velten, Elizabeth R.
|
|
|
|
4 |
p.
|
article
|
| 58 |
Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report
|
Sheng, Jin
|
|
|
|
4 |
p.
|
article
|
| 59 |
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
|
Jebbink, M.
|
|
|
|
4 |
p.
|
article
|
| 60 |
Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019
|
Li, Wenbin
|
|
|
|
4 |
p.
|
article
|
| 61 |
Trends of Molecular Testing for Lung Cancer at the King Faisal Hospital, Kigali: Therapeutic and Survival Implications
|
Van Christ Manirakiza, Achille
|
|
|
|
4 |
p.
|
article
|
| 62 |
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
|
Katayama, Yuki
|
|
|
|
4 |
p.
|
article
|
| 63 |
Uncommon EGFR-Mutant NSCLC—One Drug Does Not Fit All
|
Wang, Yang
|
|
|
|
4 |
p.
|
article
|
Journal description